SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: staring who wrote (57223)5/2/2016 7:03:45 AM
From: Ditchdigger  Read Replies (4) of 78705
 
GILD is currently pretty dependent on their HepC drugs, in which sales have declined with providers seeking a cheaper alternative to Harvoni. The efficacy gap between the competing drugs has narrowed considerably over the past few years so price is major consideration for treatment options.(and GILD's is expensive) This field has quickly progressed with some approved drugs even almost being hopscotched such as VRTX's. While politicians scream the reality is treatment cost per patient hasn't really increased that much over the past decade. The ancillary cost savings as a result of treatment length being reduced from as much as a year down to 12 weeks add up in the over all cost of cure. Not to mention the increased % of successfully treated patients per treatment course.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News